A fast-growing Montgomery County Biotech COVID-19 released data on Wednesday showing that its COVID-19 vaccine proves effective against the surging Omicron variant. When compared to competing vaccines, the company’s drug also had a greater efficacy.
Gaithersburg-based Novavax was recently granted emergency use authorization from the European Medicines Agency (EMA) for its COVID-19 also known as Nuvaxovid or NVX-CoV2373.
After a six-month period of the first two shots administered in adults, a third booster shot of the Novavax vaccine increased antibodies 73.5-fold against the Omicron variant compared to 25-fold for the Pfizer vaccine and 37-fold for the Moderna vaccine with their third booster.
NVX-CoV2373 was developed using an alternative but more traditional method compared to the mRNA technology used to create the Pfizer and Moderna vaccines.
It is the first protein-based COVID-19 vaccine to be granted approval for use in Europe. Novavax’s novel Matrix-M platform is used to produce an engineered baculovirus containing a gene to create a modified COVID-19 spike protein. Another advantage is the vaccine is easier transport and storage requirements via versus the mRNA vaccines that require sub-zero temperatures.